A National Institutes of Health research group with extensive experience studying ebolavirus countermeasures has successfully developed a vaccine against Sudan virus (SUDV) based on the licensed Ebola virus (EBOV) vaccine. ...
Feb 3, 2023
0
67
Almost as quickly as SARS-CoV-2 turned the world on its head, the spike protein studding its surface became a molecular celebrity. It is the virus's key to our cells, hence a critical target: Many promising treatments and ...
Aug 11, 2020
0
7
Airborne and potentially deadly, the virus that causes COVID-19 can only be studied safely under high-level biosafety conditions. Scientists handling the infectious virus must wear full-body biohazard suits with pressurized ...
Jul 21, 2020
0
5
Researchers at The Rockefeller University in New York have developed new tools to rapidly test the ability of antibodies to neutralize SARS-CoV-2, the novel coronavirus responsible for the COVID-19 pandemic. The approach, ...
Jul 21, 2020
0
12
Scientists funded by the National Institutes of Health have developed an investigational vaccine that protected cynomolgus macaques against four types of hemorrhagic fever viruses endemic to overlapping regions in Africa. ...
Nov 8, 2019
0
89
A single dose of a highly diluted VSV-Ebola virus (EBOV) vaccine—approximately one-millionth of what is in the vaccine being used to help control the ongoing Ebola outbreak in the Democratic Republic of the Congo (DRC)—remains ...
Oct 18, 2019
0
1
Scientists have learned how to observe the processes of oncolytic viruses in cancer cells in real time. For the first time ever, a group of scientists from NUST MISIS and the University of Calgary (Canada) has applied intravital ...
Sep 10, 2018
0
6
The experimental Ebola vaccine dubbed rVSV-ZEBOV has shown promising signs that it can contain the spread of the prolific killer virus.
May 18, 2018
0
2
An organic chemical compound shows effective antiviral activity against Ebola virus and several other viruses, according to a study led by Georgia State University.
Mar 28, 2018
0
3
A phase 1 randomized controlled trial has found an Ebola virus disease (EVD) vaccine, developed in Canada, was well-tolerated with no safety concerns, and high antibodies were present in participants 6 months after immunization. ...
Jun 19, 2017
0
105
